Drug news

NICE recommends Comtriq from Ipsen, Nexavar from Bayer and Lenvima from Eisai as treatments for thyroid cancer.

Read time: 1 mins

Last updated:17th Feb 2018

Published:17th Feb 2018

Source: Pharmawand

The National Institute for Health and Care Excellence (NICE) has recommended Cometriq (cabozantinib) from Ipsen for treatment of rare medullary thyroid cancer and Nexavar(sorafenib) from Bayer for treatment of differentiated thyroid cancer, both for routine use in the NHS and that they be removed from the Cancer Drugs Fund.

NICE has also recommended that Lenvima (lenvantinib) from Eisai be routinely available on the NHS for differentiated thyroid cancer. Differentiated thyroid cancer is the most common form of thyroid cancer.

Learning Zone Homepage

Supportive care in oncology Learning Zone

Supportive care in oncology from a multidisciplinary team involves caring for patients with cancer, treatment adherence and adverse effect management.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Positive data for V116, an investigational, 21-valent pneumococcal conjugate vaccine specifically designed for adults

Merck Inc., known as MSD outside of the United States and Canada, announced results from STRIDE-10, a Phase III trial evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Barcelona, Spain

3 mins

Drug news

Stenoparib shows clear clinical benefit and achieves significant milestone with early conclusion of phase II trial in advanced ovarian cancer

Allarity Therapeutics, Inc. announced the early discontinuation of its Phase II clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced recurrent ovarian cancer

2 min

Drug news

Calquence (acalabrutinib)combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial

Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s Calquence (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL)

2 min

See all news